Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

Internal and Emergency Medicine

Volumn 8, Issue 4, 2013, Pages 297-305

  Carulli, Lucia ^a   Ballestri, Stefano ^a   Lonardo, Amedeo ^a   Lami, Francesca ^a   Violi, Enrico ^a   Losi, Luisa ^b   Bonilauri, Lisa ^a   Verrone, Anna Maria ^a   Odoardi, Maria Rosaria ^a   Scaglioni, Federica ^a   Bertolotti, Marco ^a   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cholesterol; Insulin resistance; Metabolic syndrome; NASH; Steatosis; Thyroid hormones; TSH

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; FERRITIN; INSULIN; THYROTROPIN;

ADULT; ARTICLE; BIOPSY; BLOOD; BODY MASS; ENDOSCOPIC ECHOGRAPHY; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER FUNCTION TEST; MALE; NONALCOHOLIC FATTY LIVER; RISK FACTOR; WAIST CIRCUMFERENCE;

ADULT; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; CHOLESTEROL; FATTY LIVER; FEMALE; FERRITINS; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER FUNCTION TESTS; MALE; RISK FACTORS; THYROTROPIN; ULTRASONOGRAPHY, INTERVENTIONAL; WAIST CIRCUMFERENCE;

EID: 84878323948     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0609-4     Document Type: Article

References (43)

1. Loria P, Carulli L, Bertolotti M, Lonardo A (2009) Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 6: 236-247.
2. Vuppalanchi R, Chalasani N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49: 306-317.
3. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415-1428.
4. Lin SY, Wang YY, Liu PH, Lai WA, Sheu WH (2005) Lower serum free thyroxine levels are associated with metabolic syndrome in a Chinese population. Metabolism 54: 1524-1528.
5. Baxter JD, Webb P (2009) Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 8: 308-320.
6. George J, Liddle C (2008) Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharm 5: 49-59.
7. Arrese M (2009) Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology 49: 348-351.
8. Wartofsky L, Dickey RA (2005) The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 90: 5483-5488.
9. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291: 228-238.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2002) American Diabetes Association: clinical practice recommendations. Diabetes Care 25: S1-147.
12. Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421.
14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
15. Brunt EM, Janney C, Di Bisceglie A et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-2474.
16. Dixon JB, Bhathal PS, O'Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91-100.
17. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923.
18. Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, Arrese M (2005) Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 15: 1148-1153.
19. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM (2005) Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15: 310-315.
20. Harnois F, Msika S, Sabaté JM, Mechler C, Jouet P, Barge J, Coffin B (2006) Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg 16: 183-188.
21. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H (2006) Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26: 39-45.
22. Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS (2007) Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 17: 45-56.
23. Park JW, Jeong G, Kim SJ, Kim MK, Park SM (2007) Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 22: 491-497.
24. Canbakan B, Senturk H, Tahan V, Hatemi I, Balci H, Toptas T, Sonsuz A, Velet M, Aydin S, Dirican A, Ozgulle S, Ozbay G (2007) Clinical, biochemical and histological correlations in a group of non-drinker subjects with non-alcoholic fatty liver disease. Acta Gastroenterol Belg 70: 277-284.
25. Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF (2007) Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int 27: 764-771.
26. García-Galiano D, Sánchez-Garrido MA, Espejo I, Montero JL, Costán G, Marchal T, Membrives A, Gallardo-Valverde JM, Muñoz-Castañeda JR, Arévalo E, De la Mata M, Muntané J (2007) IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg 17: 493-503.
27. Yamamoto M, Iwasa M, Iwata K, Kaito M, Sugimoto R, Urawa N, Mifuji R, Konishi M, Kobayashi Y, Adachi Y (2007) Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22: 498-503.
28. Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, Assimakopoulos SF, Labropoulou-Karatza C (2008) Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg. 71: 355-360.
29. Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY (2009) Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 24: 233-237.
30. Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A, Baldi S, Solito B, Giannetti M, Pinchera A, Santini F, Ferrannini E (2009) Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis. Obes Surg 19: 467-474.
31. Sookoian S, Castaño G, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ (2009) A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clin Biochem 42: 624-629.
32. Uzunlulu M, Yorulmaz E, Oguz A (2007) Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr J 54: 71-76.
33. Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, Subramanian KK, Natesan S (2009) Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: a cross-sectional study from South India. Thyroid Res 2: 2.
34. Liangpunsakul S, Chalasani N (2003) Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol 37: 340-343.
35. Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN et al (2007) Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol 5: 118-123.
36. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL (2009) Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49: 1563-1570.
37. Reinher T (2010) Obesity and thyroid function. Mol Cell Endocrinol 316: 165-171.
38. Alberiche M, Boronat M, Saavedra P, Pérez N, Marrero D, López-Plasencia Y, Varillas VF, Ríos M, Nóvoa FJ (2009) Thyrotropin levels and their relationship with cardiovascular risk factors in the island of Gran Canaria, Spain. Implications of lowering the upper reference limit of thyrotropin stimulating hormone. J Endocrinol Invest 32: 102-106.
39. Park HT, Cho GJ, Ahn KH, Shin JH, Hong SC, Kim T, Hur JY, Kim YT, Lee KW, Kim SH (2009) Thyroid stimulating hormone is associated with metabolic syndrome in euthyroid postmenopausal women. Maturitas 62: 301-305.
40. Mason RL, Hunt HM, Hurxthal L (1930) Blood cholesterol values in hyperthyroidism and hypothyroidism: their significance. New Engl J Med 203: 1273-1278.
41. D'Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G (1998) Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 33: 1213-1218.
42. Bookman ID, Pham J, Guindi M, Heathcote EJ (2006) Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int 26: 566-571.
43. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K (2007) Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol 46: 1104-1110.